Total
0
Shares
Orthocell (ASX:OCC) - Managing Director, Paul Anderson - The Market Herald
Managing Director, Paul Anderson
Source: The West Australian
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Orthocell (OCC) has been granted inclusion on the Australian Prostheses List for its CelGro Dental product
  • Inclusion on the list enables dental practitioners to receive reimbursement from private insurers for use of CelGro Dental in approved dental bone and soft tissue repair procedures, reducing costs for patients
  • The reimbursement will assist Orthocell in pursuing negotiations with multi-national dental companies and national dealers for marketing and distributing rights
  • This follows the recent U.S. and Australian market approvals for the CelGro collagen medical advice
  • Orthocell is up 2.94 per cent, trading at 52.5 cents

Regenerative medicine company Orthocell (OCC) has been granted inclusion on the Australian Prostheses List.

Orthocell received notification of the inclusion from the Australian Government Department of Health for its product, CelGro Dental. Inclusion on the list enables dental practitioners to receive reimbursement from private insurers for use of CelGro Dental in approved dental bone and soft tissue repair procedures, which ultimately reduces costs for patients.

This follows the recent U.S. and Australian market approvals for the CelGro collagen medical advice, allowing it to be introduced into the dental bone and tissue regeneration market, which is estimated at US$1 billion (roughly A$1.28 billion) per year.

CelGro Dental, recently renamed Striate+, is manufactured in WA and is designed to deliver improved patient outcomes through tissue integration qualities and improved bone healing. Clinical studies of the product have shown it can support the transition from two-stage to single-stage dental procedures, reducing the procedure time by several months.

The reimbursement from private insurers will assist Orthocell in pursuing negotiations with multi-national dental companies and national dealers for marketing and distributing rights.

The company says with the U.S., Europe and Australian market approval achieved and key opinion leaders actively engaging with the program, Orthocell is well-positioned to secure distribution partners and establish CelGro as a premium dental collagen membrane.

“Inclusion of CelGro Dental on the Prostheses List is the culmination of translational research and a regulatory program to bring this product to the Australian market. I am delighted that patients now have access to a premium dental membrane product designed, manufactured and reimbursed in Australia,” said Orthocell Managing Director, Paul Anderson.

Inclusion on the Australian Prostheses list has been received ahead of the company’s previously reported expectations.

Orthocell is up 2.94 per cent on the back of this news, trading at 52.5 cents at 10:45 am AEDT.

OCC by the numbers
More From The Market Herald
Telix Pharmaceuticals (ASX:TLX) - CEO, Dr. Christian Behrenbruch - The Market Herald

" TGA fast tracks evaluation of Telix Pharmaceuticals’ (ASX:TLX) cancer imaging product

The Theraputic Goods Administration (TGA) has commenced a priority evaluation process for Telix Pharmaceuticals’ (TLX) prostate cancer imaging product, Illuccix.
Pharmaxis (ASX:PXS) - CEO, Gary Phillips (left) - The Market Herald

" Pharmaxis (ASX:PXS) to raise $4.4M via placement

Pharmaxis (PXS) has received firm commitments to raise $4.4 million through a placement.
Universal Biosensors (ASX:UBI) - CEO, John Sharman - The Market Herald

" Universal Biosensors (ASX:UBI) toasts new distribution agreement for wine testing device

Universal Biosensors (UBI) has entered into a non-exclusive agreement with Singularity SpA to distribute its wine testing platform device in Chile.
Paradigm Biopharmaceuticals (ASX:PAR) - Chairman & CEO, Paul Rennie - The Market Herald

" Paradigm Biopharmaceuticals (ASX:PAR) enrols first participant in osteoarthritis trial

Paradigm Biopharmaceuticals (PAR) has enrolled its first patient in its knee osteoarthritis (OA) biomarker study in Box Hill, Victoria.